Novavax COVID-19 Vaccine has been shown to be 89% effective in large-scale UK trials. First to Demonstrate Clinical Efficacy Against COVID-19 and Both UK and South Africa Variants.

Background: Biotech Company Novavax announced in March that it has produced a stable, prefusion protein nanoparticle vaccine candidate for COVID-19. A Phase 1/2 trial evaluating NVX-CoV2373 began on 25 May. Study Design: A randomized, observer-blinded, placebo-controlled trial of 130 healthy participants 18 to 59 years of age at two s...

NVX‑CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS‑CoV‑2, the virus that causes COVID-19 disease. NVX‑CoV2373 is a stable, prefusion protein made using Novavax’ proprietary nanoparticle technology and includes Novavax’ proprietary Matrix‑M™ adjuvant.NVX‑CoV2373 was created using Novavax’ recombinant nanop...

Maryland-based Novavax makes vaccines by sticking proteins onto microscopic particles. Engineered from the genetic sequence of COVID-19, we used our recombinant nanoparticle technology to generate antigen derived from the coronavirus spike protein. The company launched trials for a Covid-19 vaccine in May.Phase 1 & Phase 2 TrialIn t...